| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The U.S. Food and Drug Administration (FDA) is set to launch a pilot program to fast-track the review of nicotine pouches from ...
-Reuters
Oppenheimer analyst Ian Zaffino maintains Turning Point Brands (NYSE:TPB) with a Outperform and raises the price target from...
Turning Point Brands (NYSE:TPB) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0....
Needham analyst Gerald Pascarelli initiates coverage on Turning Point Brands (NYSE:TPB) with a Hold rating.